Serotonin and Behavior contains the proceedings of the 1972 symposium on the behavioral effects of changes in brain serotonin, held at Stanford University in California. The papers explore the role of serotonin in behavior as well as the key biochemical and pharmacological issues involved in behavioral studies of severe psychiatric disorders in both humans and animals. The book is organized into eight sections comprised of 65 chapters, with topics ranging from the fundamental biochemistry and pharmacology of the enzymes synthesizing serotonin, particularly, tryptophan hydroxylase and its inhibitors, to the physiology and pharmacology of serotonin. Some papers discuss the link between the telencephalic content of serotonin and pain sensitivity. Other papers focus on the effects of altering serotonin on neurons in the central nervous system. There are chapters that explain the effects of altering serotonin on animal behavior, the relationship between serotonin and sleep, the use of high doses of probenecid to estimate central serotonin turnover in affective disorders and addicts, the behavioral and metabolic effects of L-tryptophan in unipolar depressed patients taking methadone, and amygdala unit activity as a reflection of functional changes in brain serotonergic neurons. Biochemists, pharmacologists, psychiatrists, psychologists, and anyone interested in psychopharmacology will find this book extremely useful.
CONTRIBUTORS
Amnon Z. Abramowitz, M.D., Section on Intermediary Metabolism, Laboratory of Biomedical Sciences, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20014
George K. Aghajanian, M.D., Departments of Psychiatry and Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06519
Michael Aldrich, B.A., Department of Psychiatry, The University of Chicago, Chicago, Illinois 60637
Spyridon G.A. Alivisatos, M.D., Ph.D., Department of Biochemistry, The Chicago Medical School, Chicago, Illinois 60612
Arnold E. Andersen, M.D., Section on Intermediary Metabolism, Laboratory of Biomedical Sciences, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20014
Colin Atack, B. Sc., Department of Pharmacology, University of Göteborg, Medicinaregatan 7, Fack S-400, 33 Götebórg, Sweden
Julius Axelrod, Ph.D., Pharmacology Section, Laboratory of Clinical Sciences, National Institute of Mental Health, Bethesda, Maryland 20014
Max Baker, M.D., Section on Psychiatry, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20014
Jack Barchas, M.D., Department of Psychiatry, Stanford University School of Medicine, Stanford, California 94305
Hans G. Baumgarten and Priv. -Doz., Dr. med., Department of Neuroanatomy, University of Hamburg, U.K.E., 2 Hamburg 20, Martinstr. 52, West Germany
Richard E. Bensinger, M.D., National Eye Institute, National Institutes of Health, Bethesda, Maryland 20014
Phil A. Berger, M.D., Department of Psychiatry, Stanford University School of Medicine, Stanford, California 94305
Barry Berkowitz, Ph.D., Pharmacology Section, Department of Physiologic Chemistry, Roche Institute of Molecular Biology, Nutley, New Jersey 07110
Gerrit H. Besselaar, M.D., Ph.D., Department of Clinical Pharmacology, Merck, Sharp & Dohme, Rahway, New Jersey 07066
Eugene L. Bliss, M.D., Department of Psychiatry, University of Utah Medical Center, Salt Lake City, Utah 84112
Floyd E. Bloom, M.D., Laboratory of Neuropharmacology, Division of Special Mental Health Research, National Institute of Mental Health, St. Elizabeths Hospital, Washington, D. C. 20032
R. Charles Boelkins, Ph.D., Department of Psychiatry, Stanford University School of Medicine, Stanford, California 94305
William O. Boggan, Ph.D., Department of Psychiatry, The University of Chicago, Chicago, Illinois 60637
H. Keith H. Brodie, M.D., Department of Psychiatry, Stanford University School of Medicine, Stanford, California 94305
William E. Bunney, Jr., M.D., Section on Psychiatry, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20014
John S. Carman, M.D., Department of Psychiatry, The University of North Carolina School of Medicine, Chapel Hill, North Carolina 27514
Bernard J. Carroll, M.B., Ph.D.*, Department of Psychiatry, University of Melbourne, Victoria, Australia
Robert L. Conner, Ph.D., Department of Psychology, Bowling Green State University, Bowling Green, Ohio 43403
Alec Coppen, M.D., Medical Research Council Laboratories, Neuropsychiatric Research Unit, Clinical Investigation Ward, Greenbank, West Park Hospital, Epsom, Surrey, England
Annica Dahlström, M.D., Ph.D., Institute of Neurobiology, University of Göteborg, Medicinaregatan 5, Fack S-400, 33 Göteborg, Sweden
Takeo Deguchi, M.D., Ph.D.,†, Department of Psychiatry, Kyoto University, Kyoto, Japan
William C. Dement, M.D., Ph.D., Department of Psychiatry, Stanford University School of Medicine, Stanford, California 94305
Jefferson DoAmaral, Ph.D., Department of Psychiatry, Stanford University School of Medicine, Stanford, California 94305
Jerome A. Dominic, Ph.D., Department of Pharmacology, University of Kentucky College of Medicine, Lexington, Kentucky 40506
Mary K. Fairbanks, Neuropsychology Research, Veterans Administration Hospital, Sepulveda, California 91343
James Ferguson, M.D., Department of Psychiatry, Stanford University School of Medicine, Stanford, California 94305
John D. Fernstrom, Ph.D., Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139
Daniel X. Freedman, M.D., Department of Psychiatry, The University of Chicago, Chicago, Illinois 60637
E. Martin Gál, Ph.D., M.D., Department of Psychiatry, College of Medicine, University of Iowa, Iowa City, Iowa 52240
Marc Galanter, M.D., Laboratory of Clinical Psychopharmacology, Division of Special Mental Health Research, IRP, National Institute of Mental Health, Washington, D. C. 20032
Ralph Gauen, B.S., Illinois State Psychiatric Institute, Chicago, Illinois 60612
Frederick K. Goodwin, M.D., Clinical Research Unit, Section on Psychiatry, Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, Maryland 20014
David G. Grahame-Smith, Ph.D., Medical Research Council Unit and Department of Clinical Pharmacology, c/o Nuffield Department of Medicine, Radcliffe Infirmary, Oxford, OX2 6HE, England
Richard Green, M.A., Laboratory of Clinical Psychopharmacology, Division of Special Mental Health Research, IRP, National Institute of Mental Health, Washington, D.C. 20032
Christian Guilleminault, M.D., Department of Psychiatry and Neurology, Stanford University School of Medicine, Stanford, California 94305
Gordon Guroff, Ph.D., Section on Intermediary Metabolism, Laboratory of Biomedical Sciences, National Institute of Child Health and Human Development, Bethesda, Maryland 20014
Jan Häggendal, M.D., Ph.D., Department of Pharmacology, University of Göteborg, Medicinaregatan 7, Fack S-400, 33 Göteborg, Sweden
H.J. Haigler, Ph.D., Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06519
Colin D. Hall, M.B., Ch.B., Department of Neurology, The University of North Carolina School of Medicine, Chapel Hill, North Carolina...
Erscheint lt. Verlag | 2.12.2012 |
---|---|
Sprache | englisch |
Themenwelt | Medizin / Pharmazie ► Gesundheitsfachberufe |
Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
Naturwissenschaften ► Biologie ► Biochemie | |
Naturwissenschaften ► Physik / Astronomie ► Angewandte Physik | |
Technik | |
ISBN-10 | 0-323-14366-0 / 0323143660 |
ISBN-13 | 978-0-323-14366-0 / 9780323143660 |
Haben Sie eine Frage zum Produkt? |
Größe: 71,6 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
Größe: 18,0 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich